PMID- 20939811
OWN - NLM
STAT- MEDLINE
DCOM- 20110704
LR  - 20211203
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
VI  - 17
IP  - 35
DP  - 2010
TI  - PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.
PG  - 4326-41
AB  - The phosphoinositide 3-kinase (PI3K)/serine-theronine protein kinase Akt (also 
      known as protein kinase B (PKB))/mammalian target of rapamycin (mTOR) pathway is 
      a vital transduction cascade that is connected with many essential cellular 
      activities, such as growth and survival. Along with extensive pharmacological 
      studies validating the therapeutic potential of targeting the PI3K/Akt/mTOR 
      pathway for the treatment of cancer, kinase inhibitors targeting significant 
      knots of this pathway including PI3K, Akt, mTOR, and 3-phosphoinositide-dependent 
      protein kinase-1 (PDK-1) keep arising and entering clinical studies. Herein, we 
      review the most up-to-date landscape on developing small-molecule kinase 
      inhibitors targeting the PI3K/Akt/mTOR pathway, with emphasis on small-molecule 
      inhibitors which have been progressed into clinical studies.
FAU - Wu, P
AU  - Wu P
AD  - ZJU-ENS Joint Laboratory of Medicinal Chemistry, College of Pharmaceutical 
      Sciences, Zhejiang University, Hangzhou 310058, China.
FAU - Hu, Y-Z
AU  - Hu YZ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/chemistry/metabolism/*pharmacology
MH  - Humans
MH  - Molecular Structure
MH  - Neoplasms/*drug therapy/metabolism
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - *Phosphoinositide-3 Kinase Inhibitors
MH  - Protein Kinase Inhibitors/chemistry/metabolism/*pharmacology
MH  - Proto-Oncogene Proteins c-akt/*antagonists & inhibitors/metabolism
MH  - Structure-Activity Relationship
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors/metabolism
EDAT- 2010/10/14 06:00
MHDA- 2011/07/05 06:00
CRDT- 2010/10/14 06:00
PHST- 2010/07/27 00:00 [received]
PHST- 2010/10/08 00:00 [accepted]
PHST- 2010/10/14 06:00 [entrez]
PHST- 2010/10/14 06:00 [pubmed]
PHST- 2011/07/05 06:00 [medline]
AID - BSP/CMC/E-Pub/ 268 [pii]
AID - 10.2174/092986710793361234 [doi]
PST - ppublish
SO  - Curr Med Chem. 2010;17(35):4326-41. doi: 10.2174/092986710793361234.